Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

Lignende værker

• Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
  af: Ricardo D. Parrondo, et al.
  Udgivet: (2024-09-01)
• Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
  af: Ricardo D. Parrondo, et al.
  Udgivet: (2020-01-01)
• Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
  af: Ricardo D. Parrondo, et al.
  Udgivet: (2024-04-01)
• Daratumumab in relapsed or refractory immune thrombocytopenic purpura
  af: Ciprian Tomuleasa, et al.
  Udgivet: (2025-12-01)
• Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
  af: Saurav Das, et al.
  Udgivet: (2023-10-01)